Comparative Effectiveness and Safety of Upadacitinib and Vedolizumab in Biologic-Experienced Patients With Ulcerative Colitis: A Retrospective Study.

Furthermore, a higher proportion of patients treated with UPA achieved clinical response and remission at Week 14 and Week 52, though these findings did not reach statistical significance (Table 2 ).

also in 111,027 other papers